GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » YoY EBITDA Growth

HBM Holdings (FRA:6XY) YoY EBITDA Growth : -79.31% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. HBM Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was -79.31%.

HBM Holdings's EBITDA per Share for the six months ended in Dec. 2024 was €0.01.

HBM Holdings YoY EBITDA Growth Historical Data

The historical data trend for HBM Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings YoY EBITDA Growth Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial -1,737.84 88.38 -3.80 123.78 -66.67

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.34 111.49 137.18 -40.00 -79.31

HBM Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

HBM Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(0.013-0.039)/ | 0.039 |
=-66.67 %

HBM Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(0.006-0.029)/ | 0.029 |
=-79.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HBM Holdings YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of HBM Holdings's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » YoY EBITDA Growth
Comparable Companies
HKSE:09966 HKSE:06955 HKSE:01672 HKSE:02157 HKSE:02105 HKSE:02256 HKSE:02480 HKSE:02171 HKSE:02315 HKSE:01477 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
HBMHF:USA 02142:Hong Kong
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
Website
https://www.harbourbiomed.com
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

HBM Holdings Headlines

No Headlines